Linnaeus Therapeutics, Inc. is a development-stage, biotechnology company headquartered in Philadelphia, Pennsylvania. The company was launched through the UPstart incubator at the University of Pennsylvania’s Penn Center for Innovation (PCI) Ventures. Linnaeus has licensed key enabling worldwide patents from the University of Pennsylvania (“Penn”) and the University of New Mexico (“UNM”) for compounds and methods for the treatment of cancer. Linnaeus has also filed patents of its own on its lead compound LNS8801, which extend the value of Linnaeus’s licensed patent portfolio. Linnaeus is also currently focusing on developing small molecules that activate other G protein-coupled receptors to engage tumor-suppressive cellular signaling pathways.